Stocks · Health care · Pharmaceutical Preparations

Evolus, Inc.

EOLS Clue Score45
United States Fiscal year ends December CIK 0001570562 Results filed 4 Nov 2026

What the insiders did No buying or selling

By person

11 insiders · 0 transactions
5.8×

David Moatazedi holds 5.8 times base salary in stock. $4.52M of shares against $775.00K in salary for 2025.

Salary from the company's own proxy. The shares are what David Moatazedi last reported holding, valued at $9.04, the price Common Stock was last bought or sold at on the open market here, on 2 Sep 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
David Moatazedi
See Remarks
—
—
—
499,592
$4.52M
−6.3%
Rui Avelar
See Remarks
—
—
—
427,423
$3.86M
+15.9%
Vikram Malik
Director
—
—
—
321,109
$2.90M
+19.7%
Tatjana Mitchell
Chief Financial Officer
—
—
—
226,092
$2.04M
—
Sandra Beaver
Chief Financial Officer
—
—
—
167,089
$1.51M
+12.5%
Brady Stewart
Director
—
—
—
134,188
$1.21M
+161.8%
Albert G White III
Director
—
—
—
95,937
$867.13K
+316.9%
Tomoko Yamagishi-Dressler
Chief Marketing Officer
—
—
—
89,949
$813.00K
+9.2%
David N Gill
Director
—
—
—
86,887
$785.33K
+155.8%
Karah Herdman Parschauer
Director
—
—
—
77,742
$702.67K
+106.2%
Simone Blank
Director
—
—
—
77,111
$696.97K
+10.6%

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.